Health Condition 1: F411- Generalized anxiety disorder Health Condition 2: F410- Panic disorder [episodic paroxysmal anxiety] Health Condition 3: F401- Social phobias Health Condition 4: F400- Agoraphobia
Conditions
Interventions
Intervention1: Tofisopam: It will be started along with escitalopram at a dose of 50 mg once daily. Based on the response and clinical improvement, it may be increased to a maximum dose of 200 mg per
Sponsors
Kurma Ramya Krishna
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are diagnosed with any anxiety disorder according to the International Classification of Diseases (ICD-11). This includes the diagnosis of phobias, panic disorders, and generalized anxiety disorder. 2. Past diagnosis of mental illness, but not on medication for at least 3 months.
Exclusion criteria
Exclusion criteria: 1. Organic causes for the anxiety symptoms. 2. Presence of uncontrolled medical conditions such as hypertension, diabetes mellitus, bronchial asthma, etc. 3. Presence of severe medical conditions that might interfere with assessment, such as cancer, renal problems, cardiac problems, etc. 4. Pregnancy 5. Unwilling to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in scores of the Hamilton Anxiety Rating ScaleTimepoint: Changes in scores of the Hamilton Anxiety Rating Scale at baseline, 2 weeks, and 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the tolerability between the two anxiolytics by a generic assessment of the Side Effects scale.Timepoint: Baseline, 2 weeks, and 4 weeks. | — |
Countries
India
Contacts
Public ContactKurma Ramya Krishna
Konaseema Institute of Medical Sciences and Reseach foundation
Outcome results
None listed